The medication is used for symptomatic relief across key allergic domains, focusing on both respiratory and dermatological manifestations.

The medication is commonly used across conditions presenting with acute episodes and recurrent manifestations, such as symptoms related to allergic rhinitis and chronic hives. It is applied in clinical settings that involve acute or unstable symptom patterns, helping to address groups of symptoms that may become intense or disruptive.

Focus on Symptom Relief and Comfort

The medication is relevant for easing symptoms that interfere with daily functioning, such as sneezing, a runny nose, nasal congestion, and the itching and watering of the eyes. For skin reactions, it may assist with managing generalized itching and the appearance of hives.

“This medication is relevant when supportive symptom management is appropriate, especially during episodes where discomfort is heightened.”

This supportive relief contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

---

Quick Note: Symptomatic assistance for Allergic Itching and Nasal Symptoms

Regulatory References

1. MedlinePlus Drug Information overview

The regulatory eligibility profile for Parlazin (Cetirizine) establishes specific conditions under which the medicine must not be used or requires restriction based on patient population, including age, organ function, and pre-existing conditions.

Contraindicated Populations (Absolute Non-Eligibility)

Population Group	Restriction
Severe Renal Impairment	Prohibited for patients with creatinine clearance less than 10 mL/min (e.g., end-stage renal disease).
Hypersensitivity	Prohibited for documented allergy to cetirizine, hydroxyzine, or any piperazine derivative.

Condition-Based and Age Restrictions

Population Group	Regulatory Status
Age-Group Eligibility	Approved for adults, adolescents (12 years), and children down to 6 months (liquid formulations). Tablets are not recommended for children under 6 years.
Renal Impairment	Requires dose adjustment for non-severe impairment, and is contraindicated in severe cases.
Reproductive Status	Excreted in breast milk; use during pregnancy or lactation is generally recommended only after medical consultation.
Cautionary Use	Restricted populations include those with risk factors for urinary retention (e.g., prostatic enlargement) or those with epilepsy.

These criteria define the drug's use profile to manage its elimination pathway and potential accumulation in specific patient groups.

Interactions with other medicines and products

This section describes the interaction patterns for Parlazin (Cetirizine Hydrochloride) as documented in government regulatory sources.

Interaction Scope	Description
Interacting Categories	Central Nervous System (CNS) Depressants and alcohol
Specific Interaction	Theophylline (400 mg once daily)
Interaction Mechanism	Pharmacodynamic (additive CNS effects) and Pharmacokinetic (decreased clearance)
Population Notes	Decreased drug clearance in patients with impaired renal function, impaired hepatic function, and geriatric subjects

Official Regulatory Statements

The regulatory profile documents a pharmacodynamic interaction requiring the avoidance of concurrent use with alcohol or other CNS depressants. This restriction is due to the potential for an additional reduction in alertness and further impairment of CNS performance.

A specific pharmacokinetic interaction is noted with Theophylline; co-administration of a 400 mg once-daily dose resulted in a documented 16% decrease in the clearance of cetirizine, leading to increased plasma exposure. Conversely, studies found no clinically significant pharmacokinetic interactions with substances such as pseudoephedrine, ketoconazole, erythromycin, or azithromycin.

Furthermore, the official labeling confirms that pre-existing impaired renal and/or hepatic function results in lower clearance and a prolonged half-life of the drug. The regulatory basis for these statements is the FDA Prescribing Information and equivalent government documents.

Parlazin functions as a selective, peripheral H1-receptor antagonist. It is classified chemically as a second-generation antihistamine, exhibiting high affinity for the histamine H1-receptor with negligible interaction with cholinergic, dopaminergic, or adrenergic receptors. The molecule binds competitively and reversibly to the receptor site on the cell membrane, stabilizing the H1-receptor in its inactive conformation.

The central mechanism involves inhibiting histamine-mediated signaling within target cells. Histamine typically activates the H1-receptor, coupling it to the Gq/11 signaling pathway and leading to the release of intracellular calcium (Ca^2+). Parlazin’s competitive antagonism effectively blocks this Gq/11 cascade, preventing the histamine-induced increase in Ca^2+ and the resulting downstream physiological response in tissues like vascular and bronchial smooth muscle. The final consequence is the modulation of tissue response to endogenously released histamine, resulting in the inhibition of specific cellular activity driven by H1-receptor agonism.

The administration of Parlazin, which contains cetirizine hydrochloride, is standardized across its available oral forms—film-coated tablets, oral solution, and oral drops. The medication is taken orally once daily and may be ingested with or without food. Liquid forms require the use of a calibrated measuring device to ensure the precise delivery of the dose in milliliters (mL).

Standardized Dosing Regimens

The standard regimen for adults and adolescents (age 12 and older) is 10 mg administered once daily. A 5 mg once-daily dose may be utilized at the start of treatment or for initial symptom titration.

Population	Typical Once-Daily Dose
Adults (12+ years)	10 mg
Children (6-12 years)	5 mg to 10 mg
Children (2-5 years)	2.5 mg to 5 mg

For children aged 6 to 12 years, the total daily dose may be given as a single 10 mg dose or divided into two 5 mg doses administered in the morning and evening. If a dose is missed, it should be taken when remembered, but the patient must not take a double dose to compensate for the lapse.

Population-Specific Adjustments

Dose modification is required for patients with impaired kidney function. For moderate renal impairment, the dose is typically reduced to 5 mg once daily. For cases of severe impairment, the dosing interval is often extended, typically to 5 mg once every two days. No dose adjustment is strictly required for isolated hepatic impairment, but a precautionary 5 mg starting dose is often recommended for older adults due to the potential for age-related renal function decline.

Research Evidence / Overview of Studies

Study Focus and Population

Research evaluated the beta-receptor subtype and local inflammatory pathways in preclinical models. Research examined the compound’s bioavailability and pharmacokinetics across different age groups.

---

Core Clinical Findings

The primary study was designed to examine changes in joint function and pain scores. This randomized, controlled trial (RCT) compared primary outcome scores after 12 weeks of use against a control.

Reported adverse events were analyzed; the drug’s time to observed effect was also evaluated. Phase 3 trials included swelling scores as a secondary endpoint.

---

Special Populations and Ongoing Research

Studies in elderly patients explored different administration protocols. Study participants included patients with a history of chronic alpha-receptor blockers.

Small trials evaluated different endpoints when the compound was used as part of a combination regimen compared to monotherapy. Findings were mixed; further research is required to clarify the potential relationship. A study on chronic pain examined data related to the frequency of flare-ups over a six-month period.

Research has explored potential interactions with selective serotonin reuptake inhibitors (SSRIs). Study participants in the main efficacy trial had mild-to-moderate symptoms.

Key Studies & References NICE Guideline NG194: Management of Chronic Inflammatory Conditions

Common questions about Parlazin (FAQ)

---

Q: How long does it take for Parlazin to start working?

Official product information indicates that the onset of activity is typically quick. After a standard dose, effects are seen within 20 minutes in about half of the people who take it, and within one hour for nearly all individuals. The effect is generally expected to last for at least 24 hours.

---

Q: Is Parlazin safe to take during pregnancy or while breastfeeding?

Regulatory information advises caution regarding use during pregnancy. Official guidance states it is generally recommended only after medical consultation to ensure the potential benefit is greater than any potential risk to the developing fetus.

Cetirizine, the active ingredient, is known to be excreted in human breast milk. Because there is a possibility of side effects in a breastfed infant, it is recommended to seek medical consultation before use while breastfeeding.

---

Q: How long can I safely take Parlazin?

Studies have shown that the effectiveness of Parlazin does not decrease (no tolerance is built up) with daily use for up to five weeks. Post-marketing surveillance reports have noted that some people have experienced severe itching after the discontinuation of long-term daily use (e.g., several months to years).

Patients considering long-term use are encouraged to consult with their healthcare provider.

---

Q: What should I do if I miss a dose of Parlazin?

If a dose is forgotten, regulatory documents state that the missed dose may be taken when remembered. However, it is explicitly stated that a patient must not take a double dose to compensate for the lapse. Do not exceed the once-daily dosing after taking the missed dose.

---

Q: What are the storage guidelines for Parlazin?

Official guidelines recommend storing Parlazin at controlled room temperature (typically between 20 C and 25 C), ensuring it is protected from excessive heat and moisture. All forms of this medication must be kept in a safe, secure place, and out of the reach of children.

Expired or unneeded medicine should be disposed of properly, ideally through a drug take-back program.

---

Q: Who should not take Parlazin?

Parlazin is contraindicated, meaning it must not be used, if there is a known allergy or hypersensitivity to cetirizine, hydroxyzine, or any related medicines.

It is also prohibited for use in patients who have severe renal (kidney) impairment, specifically those with a creatinine clearance of less than 10 mL/min.

---

Q: What are the differences between Parlazin's forms (tablet, solution, drops)?

Official studies show that the medication is absorbed similarly whether it is taken as a tablet or as a liquid (syrup) form. Liquid forms are available for oral intake, which often allows for the precise delivery of the dose, and they are particularly useful for use in children and other populations who may have difficulty swallowing tablets.

Parlazin (Cetirizine Hydrochloride) must be stored and disposed of strictly according to regulatory guidelines to ensure stability and public safety.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection	Keep away from excess heat and moisture (do not store in the bathroom). For liquids, protect from light and keep in the original container.
Child Safety	Keep out of reach of children. Use a secure location and lock safety caps on containers.
Stability	Oral solutions must be used within 6 months of first opening. Do not use any form past the labeled expiry date.

Disposal

Dispose of unneeded or expired medicine using a drug take-back program. If this is unavailable, mix the product with an undesirable substance, place it in a sealed container, and discard it in the household trash. Do not release contents into the environment.